Skip to main content
    B

    Bright Minds Biosciences Inc (DRUG)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $20.51
    -2.10 (-9.29%)

    Market Cap: $227.96M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Bright Minds Biosciences Inc (DRUG) Stock Chart

    Updated Nov 17, 2026. Prices from end-of-day market data; valuation figures from company filings.

    Bright Minds Biosciences (DRUG) has a latest price of $20.51 on Nov 17, 2026, 83.4% below its 52-week high of $123.75. Its price fell 64.6% over the past 12 months. The month-end price rose 54.4% over the 5 years through Oct 2026, a compound annual rate of 9.1%.

    Price Chart

    From Mar 2021 to Oct 2026, its highest month-end close was $88.07 in May 2026 and its lowest $0.96 in Apr 2024, adjusted for splits.

    Month-end closes, adjusted for splits. Dividends are not included.

    Chart DRUG with Advanced Charting

    Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for DRUG.

    Free with a GNG account. No credit card.

    Price Performance

    Over the past 3 months the price fell 75.8%, and over 6 months it fell 72.5%. The month-end price rose 3,972.6% over the 3 years through Oct 2026, a compound annual rate of 244.1%.

    PeriodChange
    1 month-61.9%
    3 months-75.8%
    6 months-72.5%
    12 months-64.6%
    12 months, with dividends-64.6%
    Price change over each period. Dividends are not included unless the row says so.
    PeriodChangePer year
    3 years+3,972.6%+244.1%
    5 years+54.4%+9.1%
    From month-end closes through Oct 2026. Per year is the compound annual rate.

    Price by Year

    Its best calendar year was 2024, when the price rose 2,418.9%, and its weakest was 2022, when it fell 76.7%.

    YearCloseChange
    2026 through Oct 2026$54.98-29.5%
    2025$78.04+116.7%
    2024$36.02+2,418.9%
    2023$1.43-61.4%
    2022$3.70-76.7%
    Each year ends at its December month-end close, adjusted for splits.

    Trading Range

    The price is 56.5% below its 50-day average of $47.14 and 70.5% below its 200-day average of $69.54.

    MeasureValuePrice vs
    Latest price (Nov 17, 2026)$20.51
    52-week high$123.75-83.4%
    52-week low$17.40+17.9%
    50-day average$47.14-56.5%
    200-day average$69.54-70.5%
    Moving averages of daily closes. The last column compares the price with each level.

    Price Risk

    Over 3 years, its largest fall from a peak was 80.3%.

    MeasureValue
    1-year beta1.41
    Largest fall, 1 year-80.2%
    Largest fall, 3 years-80.3%
    Beta against the S&P 500 over one year. A fall is measured from a peak to the low after it.

    Advanced Charting Features

    Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.

    • Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
    • Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
    • Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
    • Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.

    Frequently Asked Questions About DRUG

    What is DRUG's 1-year price change?

    Bright Minds Biosciences's price fell 64.6% over the past 12 months. With dividends included, the 12-month total return was -64.6%.

    What is DRUG's 5-year price change?

    Bright Minds Biosciences's month-end price rose 54.4% over the 5 years through Oct 2026, a compound annual rate of 9.1%. These figures leave out dividends.

    What is DRUG's 52-week high and low?

    Bright Minds Biosciences's 52-week high is $123.75 and its 52-week low is $17.40. Its latest price of $20.51 on Nov 17, 2026 is 83.4% below the high.

    What is DRUG's beta?

    Bright Minds Biosciences's 1-year beta against the S&P 500 is 1.41, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 80.2%.

    Is the DRUG chart free?

    Yes. Advanced Charting for DRUG is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.